Author

Jing Su

Observed name: Su, Jing

Institutions: University of Electronic Science and Technology of China, Mianyang Central Hospital

Observed institutions: University of Electronic Science and Technology of China, Mianyang Central Hospital

ORCID: 0000-0003-2508-6771

Observed ORCID: 0000-0003-2508-6771

OpenAlex ID: A5043867920

Tregs at Diagnosis as a Potential Biomarker for Predicting High‐Risk Functionality in Newly Diagnosed Multiple Myeloma

2025 · Qiaolin Zhou, Fang Xu, et al. · Cancer Medicine · 5

Elevated serum IL-10/IL-6 ratio as a novel biomarker for secondary central nervous system lymphoma and poor prognosis in DLBCL

2025 · Jingjing Wen, Xingyu Nie, et al. · Frontiers in Immunology · 4

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients

2022 · Qiaolin Zhou, Fang Xu, et al. · Clinical and Experimental Medicine · 3

Efficacy Analysis of Bortezomib Combined with Lenalidomide in Newly Diagnosed Multiple Myeloma with 1q21 Gain/Amp

2024 · Qiaolin Zhou, Jingjing Wen, et al. · Technology in Cancer Research & Treatment · 1

A novel PEGylated form of granulocyte colony-stimulating factor, mecapegfilgrastim, for peripheral blood stem cell mobilization in patients with hematologic malignancies

2023 · Jingjing Wen, Qiaolin Zhou, et al. · BMC Cancer · 1

[Application of Mecapegfilgrastim for Peripheral Blood Hematopoietic Stem Cell Mobilization in Patients With Hematologic Neoplasms and Analysis of Predictors for Poor Mobilization].

2023 · Jing-Jing Wen, Lin Shi, et al. · PubMed Central · 1

The proportion of peripheral CD4⁺ cells within CD47⁺ lymphocytes is associated with survival outcomes in diffuse large B-cell lymphoma

2026 · Qiaolin Zhou, Jingjing Wen, et al. · European journal of medical research

Works count: 9

Citation count: 15

H-index: 3

I10-index: